Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Comment by Noloon Jun 11, 2019 6:39am
93 Views
Post# 29814349

RE:RE:RE:RE:MIXED COMMENTS

RE:RE:RE:RE:MIXED COMMENTS
leSpeculateur wrote: No Nolo, it doesn't asnwer my question. My concern is not about how they will process the sample, my doubt is about how they will sell they Cancer Screening Test a success in other country when they are not able in the USA.



Then you need to write your 'fundamental questions' better because you clearly stated: 'how it will achive the goal in other country, starting from nothing, no lab, no staff.'

And how do you know that they are not able to sell Colonsentry in the USA? Did Tripp sent you the Q2 numbers in advance yesterday? I'm not talking about Q1. I'm talking about Q2, what's happening right now as you read this. If they are 'not able to sell', as you say, that means there is no progress made. I'm curious to see what info you have on this since you seem pretty sure of what you're saying. Can you share the data with us, please? That would be awesome of you. 
Bullboard Posts